AA
BCYC

ALPS Advisors’s Bicycle Therapeutics BCYC Stock Holding History

ALPS Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Buy
51,122
+10,471
+26% +$48K ﹤0.01% 1153
2026
Q1 		$189K Sell
40,651
-344
-0.8% -$1.97K ﹤0.01% 1029
2025
Q4 		$290K Buy
40,995
+16,872
+70% +$124K ﹤0.01% 941
2025
Q3 		$187K Sell
24,123
-1,634
-6% -$12.3K ﹤0.01% 1009
2025
Q2 		$179K Buy
+25,757
New +$205K ﹤0.01% 1010
2022
Q4 		– Sell
-16,186
Closed -$376K – 1032
2022
Q3 		$376K Sell
16,186
-1,404
-8% -$33.4K ﹤0.01% 670
2022
Q2 		$295K Buy
+17,590
New +$371K ﹤0.01% 822

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

ALPS Advisors's BCYC Position: Q2 2026 in Review

ALPS Advisors increased its Bicycle Therapeutics (BCYC) stake by 26% in Q2 2026, buying an estimated $48K and bringing the position to 51,122 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #1153.

ALPS Advisors first reported a position in BCYC in Q2 2022 and has held it in 7 quarters since. The position peaked at $376K in Q3 2022. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • ALPS Advisors held 51,122 shares of Bicycle Therapeutics worth $217K as of Q2 2026.
  • ALPS Advisors bought 10,471 Bicycle Therapeutics shares in Q2 2026, an estimated $48K.
  • Bicycle Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #1153 holding.
  • ALPS Advisors first reported a position in Bicycle Therapeutics in Q2 2022 and has held it in 7 quarters since.
  • ALPS Advisors's Bicycle Therapeutics position peaked at $376K in Q3 2022.
  • 104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.